Regeneron Pharmaceuticals, Inc. R&D Chief Reveals Allergy Drug May Be Darling Of Its Pipeline

(Reuters) - Regeneron Pharmaceuticals Inc has quickly become one of the world's biggest biotech companies thanks to its Eylea treatment for macular degeneration, but its little known experimental allergy drug could become equally successful, senior company executives said in interviews.

The allergy drug, dupilumab, is meant to treat underlying causes of asthma, eczema and nasal polyps and could transform treatment of those suspected related ailments, the officials say.

"We have a lot of debate within the company as to which of our many programs is the most exciting, and a lot of people are voting on dupilumab," Regeneron research chief George Yancopoulos said in an interview at company headquarters.

Help employers find you! Check out all the jobs and post your resume.